Co-Authors
This is a "connection" page, showing publications co-authored by Sharon Yeatts and Lydia Foster.
Connection Strength
1.133
-
An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolism. Clin Trials. 2022 Dec; 19(6):636-646.
Score: 0.211
-
Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022 07; 53(7):2204-2210.
Score: 0.207
-
Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
Score: 0.119
-
Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022 04; 53(4):1149-1156.
Score: 0.050
-
Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med. 2021 11 18; 385(21):1951-1960.
Score: 0.050
-
Why Are Women Less Represented in Intracerebral Hemorrhage Trials? Stroke. 2021 01; 52(2):442-446.
Score: 0.048
-
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019 05; 18(5):428-438.
Score: 0.042
-
Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
Score: 0.037
-
Endovascular Therapy Demonstrates Benefit over Intravenous Recombinant Tissue Plasminogen Activator Based on Repeatedly Measured National Institutes of Health Stroke Scale. Interv Neurol. 2017 Mar; 6(1-2):25-30.
Score: 0.035
-
Association Between CT Angiogram Collaterals and CT Perfusion in the Interventional Management of Stroke III Trial. Stroke. 2016 Feb; 47(2):535-8.
Score: 0.033
-
Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
Score: 0.032
-
Differential Effect of Baseline Computed Tomographic Angiography Collaterals on Clinical Outcome in Patients Enrolled in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1239-44.
Score: 0.032
-
Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. J Neurointerv Surg. 2015 Nov; 7(11):795-802.
Score: 0.031
-
Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials. Stroke. 2014 Dec; 45(12):3606-11.
Score: 0.031
-
Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014 Oct; 273(1):202-10.
Score: 0.030
-
Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial. Stroke. 2014 Jun; 45(6):1791-8.
Score: 0.030
-
Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):567-74.
Score: 0.030
-
Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014 Mar; 45(3):759-64.
Score: 0.029
-
Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014 Feb; 45(2):444-9.
Score: 0.029
-
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
Score: 0.027